Novocure Announces Pivotal LUNAR Study in Non-Small Cell Lung Cancer Met Primary Overall Survival Endpoint

- Publicidad -

Novocure (NASDAQ: NVCR) today announced the LUNAR study met its primary endpoint, demonstrating a statistically significant and clinically meaningful improvement in overall survival over standard therapies alone. The LUNAR study is a pivotal, open-label, randomized study evaluating the safety and efficacy of Tumor Treating Fields (TTFields) together with standard therapies for stage 4 non-small cell lung cancer (NSCLC) following progression while on or after treatment with platinum-based therapy.

The LUNAR study also showed a statistically significant and clinically meaningful improvement in overall survival when patients were treated with TTFields and immune checkpoint inhibitors (ICI), as compared to those treated with immune checkpoint inhibitors alone, and a positive trend in overall survival when patients were treated with TTFields and docetaxel versus docetaxel alone. Patient enrollment was well balanced between the ICI and docetaxel cohorts of the experimental and control arms, and control arms performed in line with prior studies. TTFields therapy was well tolerated by patients enrolled in the experimental arm of the study.

- Publicidad -

“We are pleased with the positive readout of the LUNAR study. Prior to LUNAR, the last phase 3 trial to lead to significant improvement in overall survival in late-stage, platinum-resistant non-small cell lung cancer was six years ago, underlining the difficulty in treating this disease,” said William Doyle, Novocure’s Executive Chairman. “We are also pleased by the profound performance of the TTFields together with immunotherapy, which has the potential to meaningfully extend patient survival beyond what was previously possible. I would like to thank our patients and investigators for their courage and dedication in completing LUNAR. And, I would like to thank Novocure’s employees for their unrelenting commitment to patients and their perseverance in propelling Novocure to this major milestone.”

Novocure plans to release the full results of the LUNAR study at a future medical conference. Novocure expects to file a Premarket Approval application with the U.S. Food and Drug Administration (FDA) in the second half of 2023. Novocure also expects to file for a CE Mark in the European Union concurrently with the FDA submission.

- Publicidad -

Más del autor

Artículos relacionados

Lo más reciente

Condenaron a joven por golpear con unas piedras a un comerciante hasta causarle la muerte en medio de una presunta venganza

Condenaron a 10 años de prisión a Enmanuel Idrogo Boada, de 23 años de edad, por la muerte del comerciante Oscar Alexander Mariño, de...

Muere excontralor regional y cuatro personas resultaron heridas en un tiroteo en Ocumare de la Costa

Un fallecido y cuatro heridos dejó un tiroteo que se registró este domingo 23 de junio en el sector La Boca en Ocumare de La...

Mbappé «mejora cada día» y quiere jugar contra Polonia en la Eurocopa

El astro francés Kylian Mbappé parece estar más cerca de regresar a la Eurocopa. El delantero del Real Madrid sufrió una fractura en la nariz...

¿Quieres recibir las notas de mayor interés en tu email?

Comparte con nosotros tu email y te haremos llegar las noticias de mayor relevancia directo a tu correo